Loading clinical trials...
Loading clinical trials...
Tamoxifen and aromatase inhibitors are two oral hormonal therapies (OHT) that decrease the risk of breast cancer recurrence by over 30 %. Their efficacy however strongly depends on the duration of use...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Luxembourg Institute of Health
Collaborators
NCT06347068 · Breast Cancer, Relapse, and more
NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more
NCT07655934 · Breast Cancer
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
NCT07436078 · Female Breast Cancer, Prostate Cancer, and more
Centre Hospitalier Emile Mayrisch (CHEM)
Esch-sur-Alzette
Centre Hospitalier de Luxembourg (CHL)
Luxembourg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions